Table 2 Clinical data of 12 patients who had malignancy
| Â | Age (years) | Sex | Diagnosis | ILD | Malignancy (n = 12) | Detected autoantibodies | ||
|---|---|---|---|---|---|---|---|---|
|  |  |  |  |  | Time of detection†(months) | Primary site | Cancer-associated myositis |  |
1 | 56 | F | DM | - | -11 | Esophagus | Yes | Anti-p155/140 |
2 | 46 | F | DM | - | +18 | Breast | Yes | Anti-Mi2 |
3 | 59 | M | DM | - | -1 | Stomach | Yes | Anti-p155/140 |
4 | 53 | F | DM | - | 0 | Lung | Yes | Anti-p155/140 |
5 | 74 | F | PM/SLE | + | - 48 | Stomach | No | Anti-PL-7 |
6 | 57 | M | PM | - | 0 | Liver | Yes | none |
7 | 36 | F | DM/SLE | + | -1 | Thyroid | Yes | Anti-PL-12 |
8 | 36 | M | DM | - | 0 | Lymphoma | Yes | Anti-p155/140 |
9 | 50 | F | DM | - | -2 | Breast | Yes | Anti-p155/140 |
10 | 61 | M | DM | + | +22 | Lymphoma | Yes | Anti-Jo-1 |
11 | 68 | M | DM | - | +2 | Lung | Yes | none |
12 | 65 | M | PM | + | 0 | Stomach | Yes | Anti-Jo-1 |